177 related articles for article (PubMed ID: 23442359)
1. Cancer cells acquire resistance to anticancer drugs: an update.
Lu HP; Chao CC
Biomed J; 2012; 35(6):464-72. PubMed ID: 23442359
[TBL] [Abstract][Full Text] [Related]
2. Identification and functional analysis of genes which confer resistance to cisplatin in tumor cells.
Wu ZZ; Lu HP; Chao CC
Biochem Pharmacol; 2010 Jul; 80(2):262-76. PubMed ID: 20361941
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic mechanisms in tumorigenesis, tumor cell heterogeneity and drug resistance.
Wilting RH; Dannenberg JH
Drug Resist Updat; 2012; 15(1-2):21-38. PubMed ID: 22356866
[TBL] [Abstract][Full Text] [Related]
4. Differences in gene expression profiles and carcinogenesis pathways involved in cisplatin resistance of four types of cancer.
Yang Y; Li H; Hou S; Hu B; Liu J; Wang J
Oncol Rep; 2013 Aug; 30(2):596-614. PubMed ID: 23733047
[TBL] [Abstract][Full Text] [Related]
5. Transcription factors and drug resistance.
Kohno K; Uchiumi T; Niina I; Wakasugi T; Igarashi T; Momii Y; Yoshida T; Matsuo K; Miyamoto N; Izumi H
Eur J Cancer; 2005 Nov; 41(16):2577-86. PubMed ID: 16209921
[TBL] [Abstract][Full Text] [Related]
6. Integrated epigenomics identifies BMP4 as a modulator of cisplatin sensitivity in gastric cancer.
Ivanova T; Zouridis H; Wu Y; Cheng LL; Tan IB; Gopalakrishnan V; Ooi CH; Lee J; Qin L; Wu J; Lee M; Rha SY; Huang D; Liem N; Yeoh KG; Yong WP; Teh BT; Tan P
Gut; 2013 Jan; 62(1):22-33. PubMed ID: 22535375
[TBL] [Abstract][Full Text] [Related]
7. Using microarrays to predict resistance to chemotherapy in cancer patients.
Lee CH; Macgregor PF
Pharmacogenomics; 2004 Sep; 5(6):611-25. PubMed ID: 15335284
[TBL] [Abstract][Full Text] [Related]
8. IGFBP-3 hypermethylation-derived deficiency mediates cisplatin resistance in non-small-cell lung cancer.
Ibanez de Caceres I; Cortes-Sempere M; Moratilla C; Machado-Pinilla R; Rodriguez-Fanjul V; Manguán-García C; Cejas P; López-Ríos F; Paz-Ares L; de CastroCarpeño J; Nistal M; Belda-Iniesta C; Perona R
Oncogene; 2010 Mar; 29(11):1681-90. PubMed ID: 20023704
[TBL] [Abstract][Full Text] [Related]
9. Role of neurofilament light polypeptide in head and neck cancer chemoresistance.
Chen B; Chen J; House MG; Cullen KJ; Nephew KP; Guo Z
Mol Cancer Res; 2012 Mar; 10(3):305-15. PubMed ID: 22246235
[TBL] [Abstract][Full Text] [Related]
10. Novel mechanisms of platinum drug resistance identified in cells selected for resistance to JM118 the active metabolite of satraplatin.
Samimi G; Kishimoto S; Manorek G; Breaux JK; Howell SB
Cancer Chemother Pharmacol; 2007 Feb; 59(3):301-12. PubMed ID: 16770583
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic changes to the MDR1 locus in response to chemotherapeutic drugs.
Baker EK; Johnstone RW; Zalcberg JR; El-Osta A
Oncogene; 2005 Dec; 24(54):8061-75. PubMed ID: 16091741
[TBL] [Abstract][Full Text] [Related]
12. Microarray analysis revealed dysregulation of multiple genes associated with chemoresistance to As(2)O(3) and increased tumor aggressiveness in a newly established arsenic-resistant ovarian cancer cell line, OVCAR-3/AsR.
Ong PS; Chan SY; Ho PC
Eur J Pharm Sci; 2012 Feb; 45(3):367-78. PubMed ID: 22178533
[TBL] [Abstract][Full Text] [Related]
13. Genetic and expression profiles of squamous cell carcinoma of the head and neck correlate with cisplatin sensitivity and resistance in cell lines and patients.
Akervall J; Guo X; Qian CN; Schoumans J; Leeser B; Kort E; Cole A; Resau J; Bradford C; Carey T; Wennerberg J; Anderson H; Tennvall J; Teh BT
Clin Cancer Res; 2004 Dec; 10(24):8204-13. PubMed ID: 15623595
[TBL] [Abstract][Full Text] [Related]
14. Enhanced expression of PCAF endows apoptosis resistance in cisplatin-resistant cells.
Hirano G; Izumi H; Kidani A; Yasuniwa Y; Han B; Kusaba H; Akashi K; Kuwano M; Kohno K
Mol Cancer Res; 2010 Jun; 8(6):864-72. PubMed ID: 20530585
[TBL] [Abstract][Full Text] [Related]
15. miRNA-34a is associated with docetaxel resistance in human breast cancer cells.
Kastl L; Brown I; Schofield AC
Breast Cancer Res Treat; 2012 Jan; 131(2):445-54. PubMed ID: 21399894
[TBL] [Abstract][Full Text] [Related]
16. Nrf2 knockdown by shRNA inhibits tumor growth and increases efficacy of chemotherapy in cervical cancer.
Ma X; Zhang J; Liu S; Huang Y; Chen B; Wang D
Cancer Chemother Pharmacol; 2012 Feb; 69(2):485-94. PubMed ID: 21842204
[TBL] [Abstract][Full Text] [Related]
17. cDNA microarray analysis of isogenic paclitaxel- and doxorubicin-resistant breast tumor cell lines reveals distinct drug-specific genetic signatures of resistance.
Villeneuve DJ; Hembruff SL; Veitch Z; Cecchetto M; Dew WA; Parissenti AM
Breast Cancer Res Treat; 2006 Mar; 96(1):17-39. PubMed ID: 16322897
[TBL] [Abstract][Full Text] [Related]
18. [Cancer-associated gene abnormalities and chemosensitivity].
Sakamoto M; Umayahara K; Sakamoto H; Kawasaki K; Suehiro Y; Kunugi T; Akiya T; Iwabuchi H; Sakunaga H; Muroya T; Kikuchi Y; Sugishita T; Tenjin Y; Gray JW; Tanaka T
Gan To Kagaku Ryoho; 1998 Oct; 25(12):1819-31. PubMed ID: 9797804
[TBL] [Abstract][Full Text] [Related]
19. Characterization of chemosensitivity and resistance of human cancer cell lines to platinum(II) versus platinum(IV) anticancer agents.
Hamberger J; Liebeke M; Kaiser M; Bracht K; Olszewski U; Zeillinger R; Hamilton G; Braun D; Bednarski PJ
Anticancer Drugs; 2009 Aug; 20(7):559-72. PubMed ID: 19491657
[TBL] [Abstract][Full Text] [Related]
20. Gene expression profiles of Hodgkin's lymphoma cell lines with different sensitivity to cytotoxic drugs.
Staege MS; Banning-Eichenseer U; Weissflog G; Volkmer I; Burdach S; Richter G; Mauz-Körholz C; Föll J; Körholz D
Exp Hematol; 2008 Jul; 36(7):886-96. PubMed ID: 18400362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
